Page last updated: 2024-08-26

paxilline and ponatinib

paxilline has been researched along with ponatinib in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bott, M; Bracho, OR; Chang, LS; Copik, AJ; Dinh, CT; Fernández-Valle, C; Garcia, J; Klingeman Plati, S; Liu, XZ; Mittal, R; Petrilli, AM; Telischi, FF; Welling, DB; Yan, D; Zou, B	1

Other Studies

1 other study(ies) available for paxilline and ponatinib

Article	Year
Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells. Oncotarget, 2017, May-09, Volume: 8, Issue:19 Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Focal Adhesion Protein-Tyrosine Kinases; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; MAP Kinase Signaling System; Neurilemmoma; Neurofibromin 2; Paxillin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridazines; Receptors, Platelet-Derived Growth Factor; Schwann Cells; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor	2017

Article

Year

Ponatinib promotes a G1 cell-cycle arrest of merlin/NF2-deficient human schwann cells.

Oncotarget, 2017, May-09, Volume: 8, Issue:19

Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Cyclin D1; Cyclin-Dependent Kinase Inhibitor p27; Focal Adhesion Protein-Tyrosine Kinases; G1 Phase Cell Cycle Checkpoints; Humans; Imidazoles; MAP Kinase Signaling System; Neurilemmoma; Neurofibromin 2; Paxillin; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Pyridazines; Receptors, Platelet-Derived Growth Factor; Schwann Cells; Signal Transduction; src-Family Kinases; STAT3 Transcription Factor

2017